Author: Bill Snyder
Jun. 23, 2020—The insula, a small region of the brain involved in diverse brain functions had widespread dysconnectivity in schizophrenia, Vanderbilt researchers found.
Jun. 18, 2020—Vanderbilt cell biologists have developed an unbiased, quantitative framework for evaluating single-cell data.
Jun. 9, 2020—After evaluating the ability of more than 1,500 monoclonal antibodies to bind and neutralize the COVID-19 virus, SARS-CoV-2, in the laboratory, AstraZeneca signed an exclusive license to six candidate antibodies in Vanderbilt’s portfolio.
Jun. 4, 2020—Vanderbilt researchers have discovered the involvement of a certain type of adenosine receptor in mediating signaling that supports tumor growth and metastasis.
Jun. 4, 2020—The investigational antiviral drug remdesivir can shorten the time to recovery in adults hospitalized with COVID-19, according to preliminary results of a clinical trial published last month in The New England Journal of Medicine.
May. 21, 2020—As Nashville cautiously begins to emerge from its two-month-long COVID-19 Safer at Home response, so too are the labs and facilities at Vanderbilt University Medical Center.
May. 19, 2020—As Nashville cautiously begins to emerge from its two-month-long COVID-19 Safer at Home response, so too are the labs and facilities at Vanderbilt University Medical Center.
May. 14, 2020—Vanderbilt Vaccine Center team isolates monoclonal antibodies against the mosquito-borne Ross River virus, which causes rash, fever and debilitating muscle and joint pain lasting three to six months.
May. 7, 2020—Researchers have developed a method to identify the primary interactions between incoming viral RNA genomes and host proteins.
Apr. 30, 2020—Monoclonal antibodies against Marburg virus — a more lethal cousin of the RNA virus that causes COVID-19 — may aid in the development of antibody "cocktails" to counter viral infection.
Apr. 8, 2020—Vanderbilt University Medical Center is teaming up with academic, governmental and corporate partners in an unprecedented, fast-tracked global effort to develop antibody-based treatments to protect people exposed to the 2019 novel coronavirus disease, COVID-19.
Apr. 8, 2020—Danny Winder and colleagues are teasing apart the actions of neurotransmitter receptors in a brain region linked to anxiety and addiction, with a goal of finding treatments for substance use disorders.